NEW YORK, Dec. 14 – Oxford GlycoSciences has extended for another year a proteomics agreement with Pfizer to discover protein biomarkers and potential drug targets for Alzheimer’s disease and atherosclerosis, OGS said Friday.

Under the terms of the renewed agreement, OGS of Oxford, UK, will continue to use its proteomics technology to identify biomarkers in areas of interest to Pfizer. In exchange, Pfizer will provide additional research funding. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.